US · LYEL · BIOTECHNOLOGY
Lyell Immunopharma, Inc. (LYEL) intrinsic value and stock valuation
$13.80as of 2026-11-21 · Mkt cap 329.58M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Lyell Immunopharma, Inc. DCF and intrinsic value
InvestorsCraft values LYEL with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from LYEL’s statements →
Lyell Immunopharma, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40K | $60K | $130K | $84.7M | $10.7M |
| Operating income | -$-203.77M | -$-358.75M | -$-247.01M | -$-187.06M | -$-214.78M |
| Net income | -$-274.45M | -$-342.99M | -$-234.63M | -$-183.12M | -$-250.22M |
| EPSd | -$-16.06M | -$-26.24M | -$-18.7M | -$-14.83M | -$-20.61M |
| Operating cash flow | -$-150.02M | -$-162.39M | -$-163.69M | -$-169.56M | -$-126.25M |
| Capital expenditure | -$-780K | -$-460K | -$-2.69M | -$-24.28M | -$-65.5M |
| Free cash flow | -$-150.8M | -$-162.86M | -$-166.38M | -$-193.83M | -$-191.75M |
| Total assets | $340.1M | $490.9M | $750M | $937.6M | $1.13B |
| Total debt | $51M | $59M | $63.2M | $67.7M | $67.8M |
| Net debt | -$-9.19M | -$-46.63M | -$-82.48M | -$-55.85M | -$-226.01M |
| Total equity | $248.2M | $382.8M | $655M | $833.3M | $929.8M |
| Cash and short-term investments | $247.2M | $370.5M | $546.2M | $640.2M | $614.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40K | $60K | $130K | $84.7M | $10.7M |
| Cost of revenue | $11.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-11.5M | $60K | $130K | $84.7M | $10.7M |
| Research and development expenses | $158.7M | $171.6M | $182.9M | $159.2M | $138.7M |
| Selling, general and administrative expenses | $45.1M | $52M | $67M | $117.3M | $89.1M |
| Other expenses | -$-11.54M | $135.2M | -$-2.79M | -$-4.75M | -$-2.32M |
| Operating expenses | $192.3M | $358.8M | $247.1M | $271.7M | $225.4M |
| Cost and expenses | $203.8M | $358.8M | $247.1M | $271.7M | $225.4M |
| Interest income | $13.1M | $24.1M | $23.5M | $7.05M | $1.17M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $11.5M | $19.6M | $20.3M | $18M | $13.6M |
| Ebitda | -$-262.91M | -$-200.64M | -$-214.38M | -$-165.1M | -$-236.59M |
| Operating income | -$-203.77M | -$-358.75M | -$-247.01M | -$-187.06M | -$-214.78M |
| Total other income/expenses, net | -$-70.67M | $15.8M | $12.4M | $3.94M | -$-35.44M |
| Income before tax | -$-274.45M | -$-342.99M | -$-234.63M | -$-183.12M | -$-250.22M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-274.45M | -$-342.99M | -$-234.63M | -$-183.12M | -$-250.22M |
| Weighted average shares outstanding | $17.1M | $13.1M | $12.6M | $12.4M | $12.1M |
| Weighted average diluted shares outstanding | $17.1M | $13.1M | $12.6M | $12.4M | $12.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $247.2M | $370.5M | $546.2M | $640.2M | $614.8M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $260.9M | $379.6M | $554.7M | $651.3M | $626.3M |
| Property, plant and equipment, net | $53.6M | $72.9M | $142.3M | $166.3M | $166.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $19M | $32M | $48.5M | $115M | $330.5M |
| Total non-current assets | $79.1M | $111.3M | $195.3M | $286.3M | $501.1M |
| Total assets | $340.1M | $490.9M | $750M | $937.6M | $1.13B |
| Accounts payable | $2.89M | $5.37M | $4.82M | $3.92M | $3.21M |
| Short-term debt | $9.07M | $7.97M | $6.27M | $4.53M | $1.17M |
| Deferred revenue | $2.54M | $0.00 | $0.00 | $0.00 | $4.99M |
| Total current liabilities | $49.4M | $53.8M | $34.5M | $37M | $46.7M |
| Long-term debt | $41.9M | $51M | $56.9M | $63.2M | $66.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $79.7M |
| Total non-current liabilities | $42.4M | $54.3M | $60.6M | $67.3M | $150.9M |
| Capital lease obligations | $51M | $59M | $63.2M | $67.7M | $67.8M |
| Total liabilities | $91.9M | $108M | $95.1M | $104.3M | $197.6M |
| Common stock | $0.00 | $30K | $30K | $30K | $20K |
| Retained earnings | -$-1.62B | -$-1.35B | -$-1B | -$-767.48M | -$-584.36M |
| Accumulated other comprehensive income (loss) | $240K | $290K | -$-90K | -$-7.6M | -$-1.62M |
| Total equity | $248.2M | $382.8M | $655M | $833.3M | $929.8M |
| Total investments | $206M | $296.9M | $449.1M | $631.6M | $651.5M |
| Total debt | $51M | $59M | $63.2M | $67.7M | $67.8M |
| Net debt | -$-9.19M | -$-46.63M | -$-82.48M | -$-55.85M | -$-226.01M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-274.45M | -$-342.99M | -$-234.63M | -$-183.12M | -$-250.22M |
| Depreciation and amortization | $11.5M | $19.6M | $20.3M | $16.5M | $13.6M |
| Stock-based compensation | $41.8M | $33.1M | $47.1M | $0.00 | $62.2M |
| Change in working capital | -$-9.89M | -$-3.12M | $3.42M | -$-82.02M | $4.01M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.34M | -$-3.23M | $1.46M | $670K | $90K |
| Net cash provided by operating activities | -$-150.02M | -$-162.39M | -$-163.69M | -$-169.56M | -$-126.25M |
| Investments in property, plant and equipment | -$-780K | -$-460K | -$-2.69M | -$-24.28M | -$-65.5M |
| Acquisitions, net | -$-41.2M | -$-31.35M | $0.00 | $0.00 | $673.5M |
| Net cash used for investing activities | $54.1M | $122.4M | $184.1M | -$-11.54M | -$-121.57M |
| Common stock issued | $50.4M | $1.4M | $2.2M | $11.1M | $391.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $50.4M | $1.33M | $1.74M | $10.6M | $401.2M |
| Net change in cash | -$-45.52M | -$-38.64M | $22.1M | -$-170.27M | $153.4M |
| Cash at end of period | $61.8M | $107.3M | $145.7M | $123.6M | $294.3M |
| Operating cash flow | -$-150.02M | -$-162.39M | -$-163.69M | -$-169.56M | -$-126.25M |
| Capital expenditure | -$-780K | -$-460K | -$-2.69M | -$-24.28M | -$-65.5M |
| Free cash flow | -$-150.8M | -$-162.86M | -$-166.38M | -$-193.83M | -$-191.75M |
Line items
Line items
Line items
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- CEO
- Lynn Seely
- Employees
- 161
- Beta
- -0.06
Explore
Frequently asked questions
What is the intrinsic value of Lyell Immunopharma, Inc. (LYEL)?
Lyell Immunopharma, Inc. (LYEL) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LYEL undervalued?
LYEL trades at a price of $13.80 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.